Company Overview
Mangoceuticals, Inc. operates within the healthcare sector, specifically focusing on the health information services industry by developing, marketing, and selling men's wellness products and services through a telemedicine platform in the United States. The company's portfolio includes erectile dysfunction solutions under the Mango brand, hair loss treatments under the Grow brand, and hormone balance offerings. As a micro-cap entity, Mangoceuticals, Inc. maintains a market capitalization of $7.94 million and employs a workforce of 3 individuals. The annual revenue generated over the trailing twelve months is $466,908. These valuation and revenue figures indicate that the company operates on a very small scale, generating limited sales volume relative to its market cap, which suggests the business is either in an early stage of commercialization or facing significant challenges in scaling its telemedicine-based product distribution to match its listed valuation.
Financial Health
The company reported revenue of $466,908 over the trailing twelve months, while simultaneously posting a net income of $-20,773,948 and an EBITDA of $-16,491,894. The substantial gap between the positive revenue of $466,908 and the deeply negative net income of $-20,773,948 reveals a cost structure where operating expenses far exceed gross profits, resulting in a massive loss for every dollar of sales generated. Despite the negative net income and EBITDA, the company generated free cash flow of $689,684, which provides a degree of financial flexibility by indicating that cash inflows from operations exceeded cash outflows for capital expenditures. However, the company holds cash reserves of $481,281 against total debt obligations of $112,167, resulting in a debt-to-equity ratio of 0.71. While the company is technically debt-funded to a degree, the current ratio stands at 0.74, which indicates that current liabilities exceed current assets, suggesting a potential liquidity constraint in meeting short-term obligations. Furthermore, the return on equity is -136.2% and the return on assets is -73.8%, metrics that reveal management has not been effective in generating positive returns on the capital invested in the business.
Valuation Assessment
The company does not have a trailing P/E ratio or a forward P/E ratio available, as indicated by the N/A figures, which implies that traditional earnings-based valuation multiples are not applicable due to the negative earnings trajectory. The price-to-book ratio is 0.43, indicating that the stock is trading at a significant discount to its book value, suggesting the market is pricing in substantial risks or a lack of tangible asset backing relative to its share price. Alternative valuation metrics such as the price-to-sales ratio of 17.00 and an EV/EBITDA of -0.39 provide context, where the high multiple relative to sales suggests the market is paying a premium for future growth potential despite current unprofitability. The stock has traded between a 52-week low of $0.16 and a 52-week high of $5.20. Without a specific current share price provided in the facts, the valuation context is defined by this wide trading range of $5.04. The beta value is 2.33, which means the stock price is expected to be highly volatile and move with significantly greater magnitude than the broader market, amplifying both potential gains and losses during market fluctuations.
Growth & Income
Mangoceuticals, Inc. experienced a revenue growth of -36.8% year over year, while earnings growth is listed as N/A due to the negative net income position. The negative revenue growth indicates a contraction in sales, and since there are no positive earnings to grow, the relationship between earnings and revenue cannot be characterized by traditional growth rates. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all of its minimal earnings or capital for reinvestment rather than distributing income to shareholders. The overall growth and income profile is characterized by declining revenue and a complete absence of dividend income, reflecting a business focused on survival and potential future product development rather than current profitability or shareholder returns.